StreetInsider.com News Articles

Pliant Therapeutics names siRNA research veteran as SVP

Tue, 20 Oct 2026 08:30:24 -0400

Pliant Therapeutics, Inc. (Nasdaq: PLRX) has appointed Craig Blanchette, Ph.D., as Senior Vice President, Research (siRNA), according to a company statement.

Dr. Blanchette joins Pliant from Switch Therapeutics, where he served as Chief Scientific Officer. At Switch, he built an RNAi discovery organization, developed a three-program pipeline and advanced two programs into IND-enabling studies. Before Switch, he held roles at Genentech, most recently as Head of Protein Chemistry, where he led oligonucleotide delivery strategy. Earlier in his career, he was a staff scientist at Lawrence Livermore National Laboratories, where he led vaccine programs using nanoparticle technology.

Dr. Blanchette holds a B.S. in

Pliant Therapeutics Appoints Craig Blanchette, Ph.D., as Senior Vice President, Research (siRNA)

Tue, 20 Oct 2026 08:30:00 -0400

Recognized leader in RNAi drug discovery with track record of advancing novel delivery platforms and therapeutics to drive Company’s integrin-mediated delivery platform

SOUTH SAN FRANCISCO, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced the appointment of Craig Blanchette, Ph.D., as Senior Vice President, Research (siRNA). Dr. Blanchette is an accomplished biopharmaceutical research and development executive with more than two decades of drug discovery and development expertise, including a deep proficiency in RNAi and oligonucleotide chemistry, as

Pliant Therapeutics Appoints Craig Blanchette, Ph.D., as Senior Vice President, Research (siRNA)

Tue, 20 Oct 2026 08:30:00 -0400

Recognized leader in RNAi drug discovery with track record of advancing novel delivery platforms and therapeutics to drive Company’s integrin-mediated delivery platform

Pliant Therapeutics Announces Upcoming Presentation at European Society for Medical Oncology Congress 2026

Mon, 19 Oct 2026 16:05:00 -0400

Features FORTIFY, the ongoing Phase 1b indication expansion trial of PLN-101095 enrolling patients with ICI-refractory solid tumors

SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced a presentation at the upcoming European Society for Medical Oncology (ESMO) Congress 2026 taking place in Madrid, Spain from October 23-27, 2026.

Poster Presentation

Title: Part 2 Cohort Expansion of a Phase I Study of PLN-101095, a Dual αvβ8/αvβ1 Integrin Inhibitor, in Combination with Pembrolizumab in Immune Checkpoint Inhibitor–Refractory Advanced Solid Tumours

Presenter: Timothy A.

Pliant Therapeutics Announces Upcoming Presentation at European Society for Medical Oncology Congress 2026

Mon, 19 Oct 2026 16:05:00 -0400

Features FORTIFY, the ongoing Phase 1b indication expansion trial of PLN-101095 enrolling patients with ICI-refractory solid tumors

Poster Presentation

Presenter: Timothy A.

Form 4 PLIANT THERAPEUTICS, For: Oct 01 Filed by: Raben David

Fri, 02 Oct 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20261002/27142570.html

Form 3 PLIANT THERAPEUTICS, For: Sep 30 Filed by: Raben David

Fri, 02 Oct 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20261002/27142541.html

Pliant Therapeutics names David Raben as chief medical officer

Wed, 30 Sep 2026 16:10:16 -0400

Pliant Therapeutics, Inc. (Nasdaq: PLRX) appointed David Raben, M.D., as chief medical officer, the clinical-stage biotechnology company announced Sept. 30, 2026.

Dr. Raben, a board-certified radiation oncologist, brings more than 30 years of experience in academic translational research, clinical care, and oncology drug development. He most recently served as chief medical officer at Bicara Therapeutics, where he oversaw clinical development of ficerafusp alfa (BCA101) across multiple indications and led clinical strategy for the company's bifunctional antibody platform.

Before Bicara, Dr. Raben was vice president of global product development and product general manager for oncology at Amgen, where he led strategy and clinical

Pliant Therapeutics Appoints David Raben, M.D., as Chief Medical Officer

Wed, 30 Sep 2026 16:10:00 -0400

Leader in targeted immuno-oncology drug development
brings three decades of academic and biopharmaceutical oncology expertise

SOUTH SAN FRANCISCO, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced the appointment of David Raben, M.D., as Chief Medical Officer. Dr. Raben brings more than 30 years of experience in academic translational research, clinical care, and oncology drug development across the biopharmaceutical sector.

“David’s deep expertise in advancing innovative and targeted oncology therapies, alongside a proven track record of leading

Pliant Therapeutics Appoints David Raben, M.D., as Chief Medical Officer

Wed, 30 Sep 2026 16:10:00 -0400

Leader in targeted immuno-oncology drug development
brings three decades of academic and biopharmaceutical oncology expertise

“David’s deep expertise in advancing innovative and targeted oncology therapies, alongside a proven track record of leading

Pliant Therapeutics gets FDA Fast Track for PLN-101095 in solid tumors

Tue, 18 Aug 2026 08:30:12 -0400

Pliant Therapeutics, Inc. (Nasdaq: PLRX) announced that the U.S. Food and Drug Administration has granted Fast Track designation to its drug candidate PLN-101095 in combination with pembrolizumab for the treatment of solid tumors resistant to immune checkpoint inhibitors.

PLN-101095 is an oral, small molecule, dual selective inhibitor of αvβ8 and αvβ1 integrins. The designation covers its use in patients whose tumors are refractory to immune checkpoint inhibitor therapy.

The drug is currently being evaluated in a Phase 1a/1b clinical trial called FORTIFY, which is enrolling patients with non-small cell lung cancer, tumors with high tumor mutational burden, or clear cell renal cell

Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors

Tue, 18 Aug 2026 08:30:00 -0400

SOUTH SAN FRANCISCO, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced the receipt of Fast Track designation from the U.S. Food and Drug Administration (FDA) for PLN-101095, an oral, small molecule, dual selective inhibitor of αvβ8 and αvβ1 integrins, in combination with pembrolizumab for the potential the treatment of solid tumors that are resistant to immune checkpoint inhibitors (ICIs). PLN-101095 is currently being evaluated in the Phase 1a/1b FORTIFY trial (NCT06270706) with data expected in 2027.

“While immune checkpoint inhibitors have fundamentally changed the oncology treatment landscape, primary

Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors

Tue, 18 Aug 2026 08:30:00 -0400

“While immune checkpoint inhibitors have fundamentally changed the oncology treatment landscape, primary

Form SCHEDULE 13G PLIANT THERAPEUTICS, Filed by: ADAR1 Capital Management, LLC

Fri, 14 Aug 2026 21:31:00 -0400

si-local-file:///var/storage/secattach/20260814/26933323.html

Form SCHEDULE 13G PLIANT THERAPEUTICS, Filed by: ADAR1 Capital Management, LLC

Fri, 14 Aug 2026 21:31:00 -0400

si-local-file:///var/storage/secattach/20260814/26933323.html

Form SCHEDULE 13G/A PLIANT THERAPEUTICS, Filed by: CITADEL ADVISORS LLC

Fri, 14 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260814/26930349.html

Form SCHEDULE 13G/A PLIANT THERAPEUTICS, Filed by: CITADEL ADVISORS LLC

Fri, 14 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260814/26930349.html

Pliant Therapeutics, Inc. (PLRX) Misses Q2 EPS by 2c

Tue, 11 Aug 2026 17:10:06 -0400

Pliant Therapeutics, Inc. (NASDAQ: PLRX) reported Q2 EPS of ($0.36), $0.02 worse than the analyst estimate of ($0.34).

For earnings history and earnings-related data on Pliant Therapeutics, Inc. (PLRX) click here.

Form 8-K PLIANT THERAPEUTICS, For: Aug 11

Tue, 11 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260811/26905798.html

Form 8-K PLIANT THERAPEUTICS, For: Aug 11

Tue, 11 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260811/26905798.html

Form 10-Q PLIANT THERAPEUTICS, For: Jun 30

Tue, 11 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260811/26905732.html

Form 10-Q PLIANT THERAPEUTICS, For: Jun 30

Tue, 11 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260811/26905732.html

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Tue, 11 Aug 2026 16:05:00 -0400

FORTIFY, a Phase 1b indication expansion trial of PLN-101095,
experiencing strong enrollment

Appointed seasoned oncology drug development leaders
Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to Board of Directors

SOUTH SAN FRANCISCO, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today provided a corporate update and reported second quarter 2026 financial results.

“In the second quarter, we continued to execute across the portfolio, led by strong enrollment in FORTIFY,” said Bernard Coulie, M.D.,

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Tue, 11 Aug 2026 16:05:00 -0400

FORTIFY, a Phase 1b indication expansion trial of PLN-101095,
experiencing strong enrollment

Appointed seasoned oncology drug development leaders
Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to Board of Directors

“In the second quarter, we continued to execute across the portfolio, led by strong enrollment in FORTIFY,” said Bernard Coulie, M.D.,

Form 3 PLIANT THERAPEUTICS, For: Jul 09 Filed by: Iannone Robert

Mon, 13 Jul 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260713/26762861.html